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How did the study come about?
Thanks to continuous improvements in therapy,
5-year survival of childhood cancer in developed
countries now exceeds 80%,1,2 leading to a growing
population of long-term survivors. As the cancer and
treatment can cause adverse effects long after the ill-
ness has been cured, assessment of long-term quality
of life (QOL), somatic, psychological and social out-
comes become increasingly important. Although
cancer in children is rare, the population impact of
late toxicities on disability-adjusted life years is con-
siderable because of the young age at diagnosis.
Up to now, many single-centre studies or clinical
trials have been published, but only few large repre-
sentative long-term follow-up studies exist, including
the Childhood Cancer Survivor Studies in the USA
(CCSS),3 Canada4 and Great Britain (BCCSS).5 These
studies found increased risks of second malignant neo-
plasms (SMNs),6 mortality7,8 and chronic medical prob-
lems such as endocrine dysfunctions, cardiovascular
problems, stroke or infertility.9–11 Psychosocial prob-
lems such as depression, anxiety and post-traumatic
symptoms have also been reported.12,13 Life-long
medical follow-up is thus recommended for high-risk
patients.14,15
For these reasons, we created a national cohort study
of all survivors of childhood and adolescent cancer in
Switzerland, the Swiss Childhood Cancer Survivor
Study (SCCSS).
What does it cover?
The SCCSS is a nationwide population-based cohort
study of all children diagnosed with cancer in
Switzerland since 1976, which aims to study long-
term consequences of childhood cancer, including
mortality, SMNs, QOL, late somatic, psychological
and social effects, health behaviours and health care.
In particular, the SCCSS aims to:
(i) determine the incidence of late effects of cancer
and treatments, including overall and cause-
specific mortality, SMNs, somatic toxicities
(endocrine disorders, infertility and pregnancy
complications, cardiovascular, pulmonary and
orthopaedic problems), health-related QOL and
psychosocial outcomes including psychological
distress, educational and professional attainment;
(ii) study associations between adverse outcomes
and prospectively collected risk factors, includ-
ing tumour (exact diagnosis, histology, cyto-
genetics, tumour stage and clinical features at
diagnosis), treatment modalities (chemother-
apy, radiotherapy, surgery), participation in clin-
ical trials, age, sex, nationality, geographic
region and socio-economic position of parents;
(iii) describe the current health-care use and med-
ical follow-up in survivors, including type of
health care, frequency of visits and uptake of
recommended screening procedures and
(iv) describe health-related behaviours and their de-
terminants in survivors compared with the gen-
eral population.
Who is in the sample?
The Swiss Childhood Cancer Survivor Study is closely
linked with the Swiss Childhood Cancer Registry
(SCCR; www.childhoodcancerregistry.ch), including
all children registered in the SCCR who survived
55 years.
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The SCCR is the population-based cancer registry for
all Swiss residents diagnosed <21 years of age with
leukaemias, lymphomas, central nervous system (CNS)
tumours, malignant solid tumours or Langerhans cell
histiocytosis.16–20 It was founded in 1976. Case ascer-
tainment is excellent for children aged 0–15 years at
diagnosis who are usually treated in one of the nine
specialized paediatric cancer centres (Figure 1).
Regular comparison of the SCCR with data sets from
cantonal cancer registries, Swiss hospital statistics,
major pathology laboratories and mortality statistics
allows the integration of patients who had not been
treated in paediatric cancer centres.
Adolescents aged 16–20 years at diagnosis are also
registered in the SCCR. However, coverage of this age
group is still unsatisfactory, because only a minority
of adolescents in Switzerland are treated in paediatric
cancer centres. Instead, care is shared between a large
and heterogeneous group of specialists and hospitals,
such that not all cases are reported.21 The SCCR aims
for a complete coverage of adolescents by the year
2015.
By 31 December 2010, the SCCR included informa-
tion on 5553 Swiss residents with cancer diagnosed at
the age of 0–15 years (Table 1). Of these, 2435 (44%)
had been diagnosed at the age of 0–4 years, 1423
(26%) at age 5–9 years and 1695 (31%) at age
10–15 years; 3143 (57%) were males and 2410 (43%)
females. The most common diagnosis was leukaemias
(34%), followed by CNS tumours (18%), lymphomas
(14%), neuroblastoma (7%), soft tissue sarcomas (6%)
renal tumours (5%) and bone tumours (5%). In total,
1395 patients (25%) had died.
The SCCSS (Figure 2) is the long-term cohort study
of all patients registered in the SCCR who survived
55 years. For the questionnaire survey 2007–11, only
children diagnosed from 1976 to 2003, in the age
group of 0–15 years, were included (N¼ 2738). From
2011, the study will be extended to include adoles-
cents diagnosed at the age of 16–20 years (n 1200),
children not treated in a paediatric cancer centre
(n 500), children diagnosed between 2003 and
2005 (n¼ 463) and children who had been registered
in the SCCR after December 2003 although diagnosed
earlier (n¼ 160, Figure 2).
What has been measured?
The data collected for the SCCR and the SCCSS come
from three sources:
(i) clinical data from medical records;
(ii) routine data on current address, vital status,
SMNs and causes of death; and
(iii) questionnaire surveys and examinations.
These are briefly described below, with details given
in Tables 2 and 3.
Figure 1 Population density map of Switzerland showing the location of the nine paediatric cancer centres. Children living
in the scarcely populated Alpine region (lower half of map) are treated in Bellinzona, St Gallen, Zurich, Bern or Lausanne
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Clinical data from medical records
Information at the time of diagnosis
Children are usually registered in the SCCR within
3 months of diagnosis with standardized forms com-
pleted by local data managers of the paediatric cancer
centres. In the SCCR, these forms are entered in the
database after verification of missing or incorrect
data. For cases not treated in paediatric cancer centres
but identified via other sources [cantonal cancer regis-
tries, pathology laboratories, mortality statistics for
death certificate only (DCO) cases], we migrate infor-
mation into the SCCR in regular intervals. If not
already available, an SCCR data manager extracts
relevant information directly from hospital records.
Table 1 Characteristics of the children registered in the Swiss Childhood Cancer Registry, by live status (diagnosed
1976–2010, aged 0–15 years at diagnosis, N¼ 5553)
Characteristics
Survivors
(n¼ 4158)
Deceased
(n¼ 1395)
Total
(n¼ 5553)
n (%)a n (%)a n (%)a
Age at diagnosis (years)
0–4.9 1830 (44.0) 605 (43.4) 2435 (43.9)
5–9.9 1059 (25.5) 364 (26.1) 1423 (25.6)
510 1269 (30.5) 426 (30.5) 1695 (30.5)
Sex
Male 2315 (55.7) 828 (59.4) 3143 (56.6)
Female 1843 (44.3) 567 (40.7) 2410 (43.4)
Language region of Switzerland
German speaking 2946 (71.5) 953 (71.8) 3899 (71.6)
French speaking 1023 (24.8) 307 (23.1) 1330 (24.4)
Italian speaking 152 (3.7) 68 (5.1) 220 (4.0)
Diagnosis (ICCC-3 main groups)
(I) Leukaemias 1380 (33.2) 507 (36.3) 1887 (34.0)
(II) Lymphomas 664 (16.0) 108 (7.7) 772 (13.9)
(III) CNS tumours 669 (16.1) 349 (25.0) 1018 (18.3)
(IV) Neuroblastoma 239 (5.8) 132 (9.5) 371 (6.7)
(V) Retinoblastoma 120 (2.9) 13 (0.9) 133 (2.4)
(VI) Renal tumours 252 (6.1) 39 (2.8) 291 (5.2)
(VII) Hepatic tumours 35 (0.8) 21 (1.5) 56 (1.0)
(VIII) Bone tumours 173 (4.2) 82 (5.9) 255 (4.6)
(IX) Soft tissue sarcomas 242 (5.8) 101 (7.2) 343 (6.2)
(X) Germ cell tumours 132 (3.2) 14 (1.0) 146 (2.6)
(XI) Other malignant epithelial neoplasms 63 (1.5) 19 (1.4) 82 (1.5)
(XII) Other and unspecified malignant neoplasms 15 (0.4) 3 (0.2) 18 (0.3)
Langerhans cell histiocytosis 174 (4.2) 7 (0.5) 181 (3.3)
Treatment
Surgery only 601 (15.7) 66 (5.1) 667 (13.0)
Chemotherapyb 2030 (53.0) 505 (38.9) 2535 (49.4)
Radiotherapyc 991 (25.8) 568 (43.8) 1559 (30.4)
BMTd 211 (5.5) 158 (12.2) 369 (7.2)
Adolescents aged 16–20 years at diagnosis are not included in this table, as their coverage in the SCCR is still incomplete.
Percentages are based upon available data for each variable.
aColumn percentages.
bWithout radiotherapy, may have surgery.
cWith or without chemotherapy or surgery.
dWith or without chemotherapy, radiotherapy or surgery.
BMT, bone marrow transplantation; n, number; ICCC-3, International Classification of Childhood Cancer, third edition.
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Information includes baseline demographic data and
detailed medical information on the tumour, therapy
and response to therapy.16,17 Diagnoses are classified
according to the International Statistical Classification
of Diseases and Related Health Problems, 10th
Revision (ICD-10), the International Classification of
Diseases for Oncology, Third Edition (ICD-O3) and
the International Classification of Childhood Cancer,
third edition (ICCC-3).22
Clinical follow-up data
As long as children are treated and followed up in
paediatric cancer centres (usually 5–10 years from
the time of diagnosis), follow-up information on re-
missions and relapses, changes in treatments and
clinical study participation is extracted annually from
patient records by local data managers. Similarly, late
effects, SMNs or deaths occurring during this period
are registered.
Routine data and linkages
First, current address, vital status and date of death
have been updated in a standardized way in 2005–10
for the whole cohort by contacting community regis-
tration offices.
Causes of death and death records are identified
periodically from the Swiss mortality statistics in the
Swiss Federal Statistical Office. The SCCR data are
linked with the anonymous mortality statistics via
Figure 2 Population of the Swiss Childhood Cancer Registry (SCCR) and the Swiss Childhood Cancer Survivor Study
(SCCSS), showing the proportion deceased and response rates to the 2007–11 questionnaire survey. aIncludes survivors
diagnosed before 1 May 2003 who were included in the SCCR after 2003. bMailing to families with survivors aged 5–15 years
is performed from October 2010 to April 2011. ICCC-3, International Classification of Childhood Cancer, third edition
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Table 2 Clinical data, routine data and survey data collected in the SCCSS: detailed description (number of participants
with available data in Table 3)
Time frame Sample addressed Description/measurements
Clinical data from medical records
Since 1976 All children in the SCCR Report of new cases: disease: prior disease, date of diagnosis, exact
tumour diagnosis, localization, stage, metastases, cytogenetics, histology
Therapy: clinical study participation, treatment protocol, surgery, chemo-
therapy, radiotherapy, bone marrow transplantation, exact treatment in-
formation for non-protocol patients
Patient: date of birth, sex, language, nationality, country of birth, address at
diagnosis, residence status, contact information, parent’s profession, par-
ent’s date of birth
Since 1976 All children in the SCCR Follow up reports from clinics: disease: details on relapse, late effects and
second malignancies
Therapy: follow-up contacts, lost to follow-up, clinical study participation,
details on treatment for first diagnosis, relapse or second malignancy
Patient: contact information, life status, date and cause of death, patient’s
paediatrician or general practitioner
Routine data and linkages
Since 2005 All children in the SCCR Updates via communities: vital status, date of death, address history
Since 2005 All deceased children in
the SCCR
Linkage with Swiss mortality statistics: causes of death
Since 2009 All linkable children in
the SCCR
Linkage with Swiss National Cohort (SNC): environmental exposures
and socio-economic situation including all information from Swiss Census
dataset (1970, 1980, 1990 and 2000), mortality and migration statistics,
and (from 2011)a birth records:
maternal and paternal education and profession
no. of rooms per person and persons per household
square metre living space per person
area-based socio-economic position index
maternal and paternal age
child’s sex, birthweight, birth length, head circumference
Since 2010 All children in the SCCR Linkage with cantonal cancer registries: assessment of secondary malig-
nancies: details of tumour diagnosis, date of diagnosis, causes of death
Surveys and examinations
1994–96 Children diagnosed
1976–89, 55 years
disease free, 52 years
off treatment, treated in
one of the eight partici-
pating SPOG clinicsb
Medical history and examination: patient’s history (medical and
psychosocial)
Standardized clinical investigation: weight, height, blood pressure, screening
audiometry (Phonac)
Laboratory: complete blood count, urinalysis, electrolytes, liver, renal,
glomerular and tubular function
Endocrinological work up: Tanner’s pubertal status, age at menarche, bone
age, fT4, TSH, FSH/LH, free -oestradiol, free testosterone, IGF-1/IGF-BP3
Rest echocardiography and ECG (patients treated with anthracylines or
mediastinal radiation)
Pulmonary function test (patients with respiratory symptoms)
Intelligence test: WISC-R < 16 years of age, WAIS-R 516 years of age
Socio-economic status of the family: score based on father’s profession and
mother’s schooling
2007–11
(ongoing)
Children diagnosed
1976–2003c who
survived 55 years
Postal questionnaire (SCCSS): personal information
Health-related quality of life
Medical care and medication, former disease, somatic and mental health
Pregnancy and children (adults)/partner and sexuality (adolescents)
Lifestyle and health behaviours
Education and social environment
ECG, electrocardiography; FSH, follicle-stimulating hormone; ft4, free thyroxin; IGF-1, insulin-like growth factor 1; IGF-BP3,
insulin-like growth factor-binding protein 3; LH, luteinizing hormone; NA, not applicable; No., number; SES, socio-economic
status; SNC, Swiss National Cohort; TSH, thyroid stimulating hormone; WISC-R, Wechsler Intelligence Scale for
Children-Revised; WAIS-R, Wechsler Adult Intelligence Scale-Revised; SCCSS, Swiss Childhood Cancer Survival Study; SCCR,
Swiss Childhood Cancer Registry; SPOG, Swiss Paediatric Oncology Group.
aChildren diagnosed in 1991–2006 were included in a first linkage study performed in 2009. The linkage will be repeated in 2011
with the entire cohort.
bParticipating Swiss Paediatric Oncology Group clinics were: Zurich, Bern, Lucerne, Lausanne, Geneva, St Gall, Aarau and Locarno.
cChildren diagnosed between 1 May 2003 and 31 December 2005 (new 5-year survivors) will receive the questionnaire in 2011.
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date of birth, date of death and place of death (the
latter two identified via community registration of-
fices). This update, first undertaken in 2005, is being
repeated regularly.
Information on peri-natal data, environmental ex-
posures and socio-economic situation for cohort par-
ticipants and matched controls can be obtained via
data linkage with the Swiss National Cohort,23 a
large national cohort study combining data from the
Swiss censuses, mortality statistics, migration records
and birth records.18
Secondly, malignant neoplasms are being assessed
(in 2010–11) via linkage with Swiss cantonal cancer
registries, organized in the National Institute for Cancer
Epidemiology and Registration (NICER; www.nicer.org).
For linkage, we use a privacy-protecting technique
using Bloom filters.24 From 2012, this linkage will
be repeated annually to detect new cases.
Surveys and examinations
A first long-term follow-up survey was performed in
1994–96.15,25–27 A total of 478 5-year survivors
attended follow-up at their former hospital for a stan-
dardized medical history, a comprehensive clinical
examination and additional investigations focusing on
somatic, psychosocial and socio-economic outcomes
[e.g. intelligence using the Wechsler Intelligence
Scale for Children/Wechsler Adult Intelligence Scale
(WISC/WAIS)28]. Liver, renal, cardiac and lung
function were investigated in various subgroups.
Participants who had received anthracyclines or medi-
astinal radiation received a cardiological examination,
and patients who had received lung irradiation or
chemotherapy with bleomycine or high-dose alkylat-
ing agents underwent lung function tests.
A second long-term follow-up survey was performed
in 2007–11 (Figure 2), involving a questionnaire to all
5-year survivors who were aged 16–19 years (N¼ 470)
or 520 years (N¼ 1647) at the time of the survey.
The mailing to survivors <16 years (N¼ 621) is on-
going (2010–11).
Methodology of the SCCSS: survey
2007–11
Study logistics
Current addresses, vital status and dates of death
for participants of the 2007–11 questionnaire survey
were updated via community registration offices
(Supplementary Figure S1). All participants with a
known address received a study information letter
from their former treating hospital. They were asked
to indicate if their address had changed, if they
required the questionnaire in a language other than
Table 3 Clinical data, routine data and survey data collected in the SCCSS: available data (n) (status December 2010,
measurements described in detail in Table 2)
Collection steps
Participants (n)
All children
in SCCR
Survivors eligible for questionnaire survey
2007–11 (SCCSS), by age at survey (years)
Children
(5–15)
Adolescents
(16–19)
Adults
(520)
Clinical data from medical records
Report of new cases 5553 621 470 1647
Follow-up reports from clinics 3726a 580 443 1604
Routine data and linkages
Updates via communities 5553 621 470 1647
Linkage with Swiss mortality statistics 1395b NA NA NA
Linkage with Swiss National Cohort (SNC) 1867c 191 252 596
Linkage with cantonal cancer registries Is currently being done for all children in the SCCR (5553)
Surveys and examinations
Medical history and examination (1994–96) 478d NAe NAe 453
Postal questionnaire (SCCSS) (2007–11) 1505f NAg 312 1193
n, number; NA, not applicable; SCCSS, Swiss Childhood Cancer Survival Study; SCCR, Swiss Childhood Cancer Registry.
aThose 1827 without follow-up report include: 1058 deceased, 132 diagnosed within the last year (2010), 637 lost to follow-up.
bIncludes deceased children only.
cChildren diagnosed in 1991–2006 were included in a first linkage study performed in 2009. The linkage will be repeated in 2011.
dEligible were children diagnosed in 1976–1989 who were disease-free for 55 years.
eThe 5-year survivors in 1994–96 have meanwhile reached an age of 520 years.
fEligible were children diagnosed in 1976–2003 who survived for 55 years (N¼ 2738, see Figure 2).
gMailing to families with survivors aged 5–15 years is performed from October 2010 to April 2011.
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the information letter (German, French or Italian) or
if they did not want to participate. After 2 weeks, they
received the questionnaire with a pre-paid return en-
velope. Non-responders were sent another question-
naire 4–6 weeks later and in case of not answering,
were contacted by phone. If they felt that the ques-
tionnaire was too long, they were offered a short ver-
sion with key questions.
Self-reported somatic health problems are validated
by comparison with medical records from general prac-
titioners or hospitals. This will be done in 2011 for
cardiac disease and SMNs, and will be extended to
other outcomes in subsequent years. Informed con-
sent for this validation has been collected in the
questionnaire.
The SCCSS questionnaire
The questionnaire was created based on those used in
the US, Canadian and UK childhood cancer survivor
studies3–5 to enable international comparison of health
outcomes. It contains the following main domains:
QOL, somatic health, current medication, health ser-
vice utilization, psychological distress, fertility, health
behaviour and socio-economic information.
In addition to the questions from the US, UK and
Canadian questionnaires, we included the Brief
Symptom Inventory (BSI) assessing psychological dis-
tress,29,30 and added more questions on health behav-
iours and socio-economic information. Unique for the
SCCSS is the inclusion of not only the cancer sur-
vivors who have reached adulthood, but also younger
5-year survivors.
To account for age-dependent differences, we cre-
ated three distinct questionnaires: for adult survivors
(aged 520 years), adolescents (aged 16–19 years) and
children (aged 5–15 years). Details of the content of
the questionnaire are described in Table 4. The ques-
tionnaires in German, French and Italian are available
on our homepage (http://www.childhoodcancerregistry
.ch/sccss).
Control data sets for the questionnaire
2007–11
For comparing answers of study participants with
healthy controls, we took two different approaches:
(i) sibling questionnaire—in 2009–11, the same
questionnaires (excluding questions on past dis-
ease and treatments) are being sent to siblings
of the study participants; and
(ii) population health surveys—in addition to ques-
tions derived from other childhood cancer sur-
vivor studies,3–5 we included questions on QOL,
health behaviours and socio-economic outcomes,
which were used during the same years in gen-
eral population health surveys in Switzerland.
This allows a straightforward comparison of
specific outcomes between survivors and the
Swiss general population (Table 4).29,31–41
Study participation and attrition
In the 1994–96 survey, the SCCR contained informa-
tion on 914 5-year survivors. All patients (n¼ 750) for
whom a valid address was found were invited to at-
tend follow-up at their former hospital, and
478 (64%) participated (Table 3).26
In the 2007–11 survey, 2738 eligible survivors were
mailed a questionnaire (1647 adults aged 20–49 years
at the survey, 470 adolescents aged 16–19 years
and 621 children aged 5–15 years; Figure 2). For
134 survivors, we had no valid address, 119 refused
and 367 did not answer. Current response rates (31
December 2010) were: 1193 adults (78% of contacted)
and 312 adolescents (69% of contacted) (Tables 3 and
5). Mailing of questionnaires to families of children
aged 5–15 years and siblings takes place from October
2010 to June 2011. Provisional response rate for the
sibling mailing is 451/749 (60%). Respondents to the
questionnaire were more likely to be female, German
speaking and aged 25–35 years compared with
non-respondents (Table 5).
What has been found? Key
findings and publications
Somatic outcomes
The first survey (1992–94) collected detailed data on
somatic and cognitive outcomes.15,25–27 Moderate to
severe late effects were found in 211/621 (34%) sur-
vivors.26 A subgroup of 140 acute lymphoblastic leu-
kaemia (ALL) survivors was studied in detail.25,27 Of
those, 21/140 (15%) had moderate to severe late ef-
fects, 8 needed special schooling and 14 had problem-
atic psychosocial adjustments. Most survivors suffered
from endocrinological abnormalities (20/140, 14%).
Problems of the cardiovascular system, lung, liver and
digestion were rare (overall 9/140, 6%).25 These find-
ings resulted in the development of Swiss recommen-
dations for long-term follow-up of childhood cancer
survivors.15
In male survivors of acute lymphoblastic leukaemia,
we assessed gonadal function and sperm quality.
While sex hormone levels were normal, sperm con-
centration and sperm counts were decreased com-
pared with WHO criteria and healthy controls,
suggesting that treatment with moderately dosed che-
motherapeutic agents, even without added radiother-
apy, might have long-term gonadotoxic effects.42
Prevalence of bronchial asthma, assessed in the
2007–11 survey in young adult survivors, was similar
to data published from general population samples in
Switzerland.43
Psychological and socio-economic outcomes
In the 2007–11 survey, we assessed psychological dis-
tress in young adult childhood cancer survivors and
found that average distress scores were similar to
normal populations. However, the proportion reporting
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high distress was disproportionally large, suggesting
that a significant number of survivors might benefit
from psychological counselling.30
A considerable proportion of childhood cancer pa-
tients had transient problems with schooling, but
final educational attainment in adulthood was com-
parable with the general population. Only CNS
tumour survivors and survivors with a relapse had
poorer outcomes.44
Health behaviours
A healthy lifestyle is important to prevent chronic dis-
eases in the general population and even more rele-
vant for childhood cancer survivors. In 835 young
adult survivors and 1670 matched controls, latent class
analysis identified four distinct behaviour patterns:
‘risk-avoiding’—with a generally healthy behaviour;
‘moderate drinking’—with higher levels of physical
activity45 but moderate alcohol consumption; ‘risk-
taking’—engaging in several risk behaviours (alcohol,
tobacco and marijuana consumption); and ‘smoking’—
including smoking but not drinking. A considerable pro-
portion of survivors and controls (14 vs 12%) engaged
in multiple risk behaviours. Survivors were more
likely to be in the ‘moderate drinking’ and less
likely to be in the ‘smoking’ group, indicating a
greater awareness of health compromising effects of
tobacco than alcohol. Compared with the general
population,46 survivors engaged in binge drinking
later in life compared with healthy peers.
Medical care in long-term survivors of
childhood cancer
Well-organized medical follow-up is important to
detect and treat late effects in survivors. However,
we found that only a minority of adult survivors of
childhood cancer in Switzerland have regular follow-
up, and few received written documentation on their
diagnosis, therapy and advice for future medical
check-ups.14 An important barrier for not attending
follow-up was the belief that follow-up is not
necessary.47
On-going and planned studies
New 5-year survivors are integrated continuously into
the SCCSS. This makes numbers of the cohort and
response rates fluctuate with time.
We plan to send the participants a follow-up ques-
tionnaire every 5 years. The next is planned for 2015.
A study funded by the European Union FP7
(PanCareSurFup; running 2011–15) pools data from
the SCCSS with data from other European countries,
to construct a European cohort of childhood cancer
survivors. It aims to describe late mortality, SMNs
and cardiac late effects and determine risk factors.
Table 4 Structure of the 2007–11 questionnaires (SCCSS), indicating source of questions and available comparison data
(three versions of the questionnaire were made for adult, adolescent and child survivors)
Sections of questionnaire
Reference questionnaires and comparison data
Adults (aged 520 years) Adolescents (aged 16–19 years) Children (aged 5–15 years)
Personal information Swiss Census 200031 Swiss Census 200031 Swiss Census 200031
SHS 200734
Health-related QOL SF-3639 SF-3639 KidScreen40
Former disease and current
health status, medical care
and medication
CCSS3 CCSS3 CCSS3
BCCSS5 BCCSS5 BCCSS5
BSIa,29,30 BSIa,29,30 SDC35
Pregnancy and children/
partner and sexuality
Own questions SMASH 2002 NA
BCCSS5
Lifestyle and health
behaviours
SHS 200734 SHS 200734 BALLABEINA36
SMASH 200232 GABRIEL37
Tobacco-Monitoring33 KIGGS-Study38
Formation and social
environment
Swiss Census 200031 Swiss Census 200031 Swiss Census 200031
European Social Survey41 SMASH 200232 SHS 200734
SHS 200734
BCCSS, British Childhood Cancer Survivor Study; CCSS, Childhood Cancer Survivor Study; KidScreen, Health-Related Quality of
Life Questionnaire for Children and Young People and their Parents; NA, not applicable; SDC, Strength and Difficulties
Questionnaire for Children; SF-36, Short Form-36 (version 2); SHS, Swiss Health Survey 2007; SMASH, Swiss Multicentre
Adolescent Survey.
aBrief Symptom Inventory (BSI) with reference data from healthy normal populations and psychotherapy patients from the
University of Bern Outpatient Clinic.
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Table 5 Characteristics of the Swiss Childhood Cancer Survivor Study population, for responders and non-responders
to the questionnaire survey 2007–11 (5-year survivors currently aged415 years, diagnosed in 1976–2003, aged 0–15
years at diagnosis, N¼ 2117: 1647 adults and 470 adolescents)
Responders
(n¼ 1505: 1193
adults and
312 adolescents)
Non-responders
(n¼ 612: 454 adults and
158 adolescents)
P-valuen (%)a n (%)a
Socio-demographic factors
Sex
Male 818 (54.4) 389 (63.6)
Female 687 (45.7) 223 (36.4) <0.001
Current age (years)
16–19.9 166 (11.0) 73 (11.9)
20–24.9 386 (25.7) 181 (29.6)
25–29.9 407 (27.0) 118 (19.3)
30–34.9 266 (17.7) 114 (18.6)
535 280 (18.6) 126 (20.6) 0.006
Language region of Switzerland
German speaking 1123 (74.6) 385 (64.5)
French speaking 341 (22.7) 182 (30.5)
Italian speaking 41 (2.7) 30 (5.0) <0.001
Clinical factors
Diagnosis (ICCC-3 main groups)
(I) Leukaemias 540 (35.9) 190 (31.1)
(II) Lymphomas 287 (19.1) 131 (21.4)
(III) CNS tumours 182 (12.1) 79 (12.9)
(IV) Neuroblastoma 60 (4.0) 31 (5.1)
(V) Retinoblastoma 34 (2.3) 20 (3.3)
(VI) Renal tumours 101 (6.7) 25 (4.1)
(VII) Hepatic tumours 10 (0.7) 2 (0.3)
(VIII) Bone tumours 70 (4.7) 24 (3.9)
(IX) Soft tissue sarcomas 81 (5.4) 41 (6.7)
(X) Germ cell tumours 47 (3.1) 24 (3.9)
(XI) Other malignant epithelial neoplasms 19 (1.3) 8 (1.3)
(XII) Other and unspecified malignant neoplasms 4 (0.3) 1 (0.2) 0.135
Langerhans cell histiocytosis 70 (4.7) 36 (5.9)
Age at diagnosis (years)
0–4.9 543 (36.1) 228 (37.3)
5–9.9 410 (27.2) 184 (30.1)
510 552 (36.7) 200 (32.7) 0.187
Time since diagnosis (years)
5–14.9 347 (23.1) 136 (22.2)
15–24.9 732 (48.6) 286 (46.7)
525 426 (28.3) 190 (31.1) 0.453
(continued)
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Radiation doses and chemotherapeutic agents
received will be studied in detail.
An on-going research programme (2009–12) on
follow-up care funded by the Swiss National Science
Foundation (SNF) studies different models of follow-
up for childhood cancer survivors in Switzerland and
Europe. In addition, all survivors in Switzerland who
replied in 2007–11 will receive a questionnaire about
their needs and desires for follow-up care after child-
hood cancer and how they would like to see it orga-
nized. Oncologists and general practitioners receive a
similar questionnaire.48–50
Two projects nested in the SCCSS (from 2011 to
2014; funded by the SNF and the Swiss Cancer
League) focus on transition from paediatric to adult
follow-up care in Switzerland.
Results from all these studies will provide the basis
to develop a standardized model of follow-up for
survivors of childhood and adolescent cancer in
Switzerland and Europe.
What are the main strengths and
weaknesses?
Strengths of the SCCSS are:
(i) the close link with the national childhood can-
cer registry and paediatric oncology clinics
allows easy access to routine data and clinical
information from medical records. Additionally,
research findings can promptly be translated
into daily practice;
(ii) the high response rate makes results represen-
tative for the majority of childhood cancer sur-
vivors in Switzerland;
(iii) the SCCSS can easily be extended to assess
later outcomes in current survivors and to
include new survivors treated with more
recent therapies; and
(iv) results of the SCCSS can be compared with re-
sults for representative population-based stu-
dies performed simultaneously in Switzerland,
with results from siblings and with other child-
hood cancer survivor studies.
Limitations of the study are:
(i) the number of survivors of certain rare cancers
and specific therapies in Switzerland is small,
limiting the ability to study rare outcomes. This
limitation can be overcome by international
pooling of data, as in the incipient EU FP7
survey; and
(ii) although the first late effects study (1994–96)
included a standardized medical examin-
ation and measurements, outcomes assessed in
2007–11 were based on self-reports from a
questionnaire. However, we will validate im-
portant outcomes with medical records.
Can I get hold of the data? Where
can I find out more?
The SCCR and the SCCSS are collaborative projects
between the Swiss Paediatric Oncology Group
(SPOG) and the Institute of Social and Preventive
Medicine, University of Bern, Switzerland. Our home-
page displays detailed information on methods, re-
sults and publications (www.childhoodcancerregistry
.ch). Researchers interested in collaborative work can
contact the principal investigators (Claudia Kuehni,
kuehni@ispm.unibe.ch and Nicolas von der Weid,
Nicolas.von-der-Weid@chuv.ch) to discuss planned
projects or analyses of existing data. The final decision
will be made upon presentation of the project to the
Scientific Council of the SPOG.
Table 5 Continued
Responders
(n¼ 1505: 1193
adults and
312 adolescents)
Non-responders
(n¼ 612: 454 adults and
158 adolescents)
P-valuen (%)a n (%)a
Therapy
Surgery only 704 (47.1) 282 (46.6)
Chemotherapyb 161 (10.8) 74 (12.2)
Radiotherapyc 517 (34.6) 228 (37.7)
Bone marrow transplantationd 114 (7.6) 21 (3.5) 0.004
Percentages are based upon available data for each variable. n, number.
aColumn percentages.
bWithout radiotherapy, may have surgery.
cWith or without chemotherapy or surgery.
dWith or without chemotherapy, radiotherapy or surgery.
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Supplementary Data
Supplementary Data are available at IJE online.
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